These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11260 related articles for article (PubMed ID: 10685653)
1. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma. Flaherty LE Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653 [TBL] [Abstract][Full Text] [Related]
2. Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma. Buzaid AC; Legha SS Semin Oncol; 1994 Dec; 21(6 Suppl 14):23-8. PubMed ID: 7992096 [TBL] [Abstract][Full Text] [Related]
3. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience. Legha SS; Ring S; Eton O; Bedikian A; Plager C; Papadopoulos N Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S9-15. PubMed ID: 9457387 [TBL] [Abstract][Full Text] [Related]
4. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma. O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850 [TBL] [Abstract][Full Text] [Related]
5. Biochemotherapy of melanoma. Keilholz U Forum (Genova); 2003; 13(2):158-65; quiz 189. PubMed ID: 14732882 [TBL] [Abstract][Full Text] [Related]
6. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. Serrone L; Zeuli M; Sega FM; Cognetti F J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932 [TBL] [Abstract][Full Text] [Related]
7. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Keilholz U; Stoter G; Punt CJ; Scheibenbogen C; Lejeune F; Eggermont AM Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S22-8. PubMed ID: 9457389 [TBL] [Abstract][Full Text] [Related]
8. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival. Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391 [TBL] [Abstract][Full Text] [Related]
9. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Legha SS; Ring S; Bedikian A; Plager C; Eton O; Buzaid AC; Papadopoulos N Ann Oncol; 1996 Oct; 7(8):827-35. PubMed ID: 8922197 [TBL] [Abstract][Full Text] [Related]
10. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. O'Day SJ; Boasberg PD; Piro L; Kristedja TS; Wang HJ; Martin M; Deck R; Ames P; Shinn K; Kim H; Fournier P; Gammon G Clin Cancer Res; 2002 Sep; 8(9):2775-81. PubMed ID: 12231516 [TBL] [Abstract][Full Text] [Related]
11. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250 [TBL] [Abstract][Full Text] [Related]
12. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Legha SS Semin Oncol; 1997 Feb; 24(1 Suppl 4):S39-43. PubMed ID: 9122733 [TBL] [Abstract][Full Text] [Related]
13. A phase II study of neoadjuvant biochemotherapy for stage III melanoma. Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232 [TBL] [Abstract][Full Text] [Related]
14. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. Ives NJ; Stowe RL; Lorigan P; Wheatley K J Clin Oncol; 2007 Dec; 25(34):5426-34. PubMed ID: 18048825 [TBL] [Abstract][Full Text] [Related]
16. Practical guidelines for the management of biochemotherapy-related toxicity in melanoma. Buzaid AC; Atkins M Clin Cancer Res; 2001 Sep; 7(9):2611-9. PubMed ID: 11555571 [TBL] [Abstract][Full Text] [Related]
17. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Liu D; O'Day SJ; Yang D; Boasberg P; Milford R; Kristedja T; Groshen S; Weber J Clin Cancer Res; 2005 Feb; 11(3):1237-46. PubMed ID: 15709194 [TBL] [Abstract][Full Text] [Related]
18. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. Eton O; Legha SS; Bedikian AY; Lee JJ; Buzaid AC; Hodges C; Ring SE; Papadopoulos NE; Plager C; East MJ; Zhan F; Benjamin RS J Clin Oncol; 2002 Apr; 20(8):2045-52. PubMed ID: 11956264 [TBL] [Abstract][Full Text] [Related]
19. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. McDermott DF; Mier JW; Lawrence DP; van den Brink MR; Clancy MA; Rubin KM; Atkins MB Clin Cancer Res; 2000 Jun; 6(6):2201-8. PubMed ID: 10873069 [TBL] [Abstract][Full Text] [Related]
20. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Bartell HL; Bedikian AY; Papadopoulos NE; Dett TK; Ballo MT; Myers JN; Hwu P; Kim KB Head Neck; 2008 Dec; 30(12):1592-8. PubMed ID: 18798304 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]